Top 10
The top ten charts the articles that have been downloaded most often, in HTML format, from the Nature Reviews Rheumatology website in recent weeks. The chart does not rank the quality, scientific significance or citation impact of the content. However, it may bring articles to your attention that you might not have otherwise noticed. We hope you enjoy them.
Top of pageTreatment of rheumatoid arthritis: state of the art 2009
Ronald F. van Vollenhoven
doi:10.1038/nrrheum.2009.182
The therapeutic options for patients with rheumatoid arthritis (RA) have changed dramatically over the past two decades, as discussed in this Review. The current landscape of RA therapy in terms of available therapeutics is described, and accepted principles of RA management and some important controversies in this field are outlined.
Case Study
Malar rash caused by metal allergy in a patient with systemic lupus erythematosus
Meghavi Kosboth, Anthony Chin-Loy, Robert Lyons, Stanton K Wesson & Westley H Reeves
doi:10.1038/ncprheum0464
Genetics: New genetic link to disease severity in RA
Jenny Buckland
doi:10.1038/nrrheum.2009.189
Review
Drug Insight: the mechanism of action of rituximab in autoimmune disease—the immune complex decoy hypothesis
Ronald P Taylor & Margaret A Lindorfer
doi:10.1038/ncprheum0424
The clinical benefits associated with rituximab therapy in patients with B-cell lymphomas or autoimmune diseases are well established. Rituximab has been hypothesized to act by promoting elimination of B cells, but in this Review the authors propose another theory to explain how this agent works in autoimmune diseases—the immune-complex decoy hypothesis.
Regulatory T cells as therapeutic targets in rheumatoid arthritis
Jonathan H. Esensten, David Wofsy & Jeffrey A. Bluestone
doi:10.1038/nrrheum.2009.183
Regulatory T cells are critically involved in immune homeostasis. Several established and experimental treatments for RA might work via effects on regulatory T cells. This Review discusses the potential benefits and pitfalls of targeting these cells to control autoimmunity.
IL-17 as a future therapeutic target for rheumatoid arthritis
Wim B. van den Berg & Pierre Miossec
doi:10.1038/nrrheum.2009.179
Interleukin-17 has been implicated in the pathogenesis of inflammatory arthritis. Evidence from animal models and preliminary results from trials in human disease highlight the emergence of this proinflammatory cytokine as a target for RA therapy.
Review
The management of Sjögren's syndrome
Clio P Mavragani, Niki M Moutsopoulos & Haralampos M Moutsopoulos
doi:10.1038/ncprheum0165
The secretory functions of the exocrine glands are impaired in patients with Sjögren's syndrome, resulting in symptoms of dry eyes and dry mouth. This Review discusses the currently available treatments for the glandular and extraglandular manifestations of this chronic autoimmune disorder, and describes potential future therapies.
Review
Potential new drug targets for osteoporosis
Chad Deal
doi:10.1038/ncprheum0977
Knowledge of the action of the bone remodeling cycle in patients with osteoporosis has led to the discovery of a number of novel targets for therapy. In this Review, Dr Deal summarizes currently available therapies and agents in development for the treatment of low bone mass and their modes of action.
Therapy: Rituximab and PML risk—informed decisions needed!
Leonard H. Calabrese & Eamonn S. Molloy
doi:10.1038/nrrheum.2009.193
